El Monte Medical Marijuana Facility Proposed Near Temple City Neighborhoods
City attorney to file comments expressing significant concerns; public meeting scheduled for Nov. 27
TEMPLE CITY, CA (Nov. 21, 2018)—In response to a medical cannabis growing and processing facility proposed near city limits, the Temple City City Council last night directed the city attorney to file comments expressing significant concerns about the El Monte project, which is adjacent to Temple City residential neighborhoods.
The proposed El Monte Medical Marijuana Park converts an existing 70,000-square-foot industrial building near Temple City Boulevard and Ellis Lane into a medical cannabis cultivation, processing and distribution facility.
In reviewing the proposed project, Temple City officials also learned of plans for an adjacent clustering of seven additional medical marijuana facilities in El Monte.
While the City of Temple City does not have authority over proposed businesses in other jurisdictions, it does have the right to comment on development projects that could affect local quality of life. In this particular case, the City Council has voiced concerns about medical marijuana businesses and their potential to cluster at city borders, as well as pose potential threats to public health and safety.
The City of Temple City’s formal comment letter on the proposed medical marijuana park will be posted to the city website by the evening of Monday, Nov. 26, at www.templecity.us.
Residents interested in voicing their concerns about the project can do so at 7 p.m. on Tuesday, Nov. 27, at El Monte City Hall East, located at 11333 Valley Blvd. Those unable to attend the meeting may submit their comments to Betty Donavanik, (626) 258-8626 or firstname.lastname@example.org.
The Temple City City Council will continue to actively monitor this project and the seven other proposed medical marijuana facilities. Updates will be provided through the city website and its social media accounts.
—To view other City news releases, visit templecity.us/pr—